Chlordiazepoxide + clidinium bromide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Peptic ulcer; Irritable bowel syndrome Each cap/tab contains chlordiazepoxide 5 mg/clidinium bromide 2.5 mg: As adjunctive therapy: Usual maintenance: 1-2 caps/tabs 3-4 times/day.
Administration
Should be taken on an empty stomach. Take 30 min-1 hr before meals.
Contraindications
Glaucoma, myasthenia gravis, obstructive gastrointestinal diseases, paralytic ileus, ulcerative colitis, benign bladder neck obstruction, prostatic hyperplasia.
Special Precautions
Patient with a history of drug abuse or acute alcoholism, depression, CV disease (e.g. CHF, coronary heart disease), respiratory disease. Patient subjected to heat exposure, strenuous exercise and dehydration, or receiving anticholinergic drugs. Elderly and debilitated patients. Renal and hepatic impairment. Avoid abrupt withdrawal (prolonged therapy). Patient Counselling This drug may impair physical or mental abilities, if affected, do not drive or operate machinery. Monitoring Parameters Monitor mental status, anticholinergic effects (e.g. CNS, bowel and bladder function); CBC, liver and renal function (as needed); respiratory and CV status (including orthostasis). Evaluate for history of addiction. Assess for signs and symptoms of CNS depression and paradoxical reactions (e.g. excitement, stimulation, acute rage).
Adverse Reactions
Significant: Paradoxical reactions (e.g. hyperactive or aggressive behaviour), impaired core body temperature regulation, sleep-related activities (e.g. sleep-driving, cooking, and eating; making phone calls while asleep), falls, withdrawal symptoms, anticholinergic effects (e.g. xerostomia, blurred vision, urinary retention); drug tolerance or psychological and physical dependence. Blood and lymphatic system disorders: Blood dyscrasias (e.g. agranulocytosis, leucopenia). Gastrointestinal disorders: Nausea, constipation. Hepatobiliary disorders: Hepatic dysfunction, jaundice. Investigations: Changes in EEG. Metabolism and nutrition disorders: Oedema. Nervous system disorders: Ataxia, confusion, drowsiness, extrapyramidal reaction, anterograde amnesia. Reproductive system and breast disorders: Menstrual irregularities, increased and decreased libido. Skin and subcutaneous tissue disorders: Skin eruption. Vascular disorders: Syncope.
Drug Interactions
Chlordiazepoxide may increase risk of CNS effect with other CNS depressants.
CIMS Class
ATC Classification
N05BA02 - chlordiazepoxide ; Belongs to the class of benzodiazepine derivatives anxiolytics. Used in the management of anxiety, agitation or tension.
Disclaimer: This information is independently developed by CIMS based on chlordiazepoxide + clidinium bromide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in